Immutep (IMMP) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immutep (IMMP) has outperformed Quince Therapeutics (QNCX) over the past year, gaining 90.1% versus a loss of 92.4%. Over five years, IMMP leads with a -2.8% price change compared with -99.8% for QNCX. Quince Therapeutics is the larger company by market cap ($29.9 million vs $28.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMP | QNCX |
|---|---|---|
| Share price | $3.84 | $29.36 |
| Market cap | $28.30M | $29.86M |
| 1-day change | -6.56% | +9.88% |
| YTD return | +34.27% | -95.62% |
| 1-year return | +90.10% | -92.35% |
| 5-year return | -2.78% | -99.77% |
| EPS (TTM) | $-7.30 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $70.60 | $910.00 |
| 52-week low | $3.80 | $15.10 |
| Distance from 52-week high | -94.56% | -96.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +681.25% | +156.91% |
| Average volume | 14.70K | 28.83K |
| Shares outstanding | 7.37M | 1.02M |
| Employees | — | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed QNCX by 182.5 percentage points over the past year.
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Healthcare · Biotechnology
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Healthcare · Biotechnology · 38 employees
IMMP vs QNCX FAQ
Which is bigger, Immutep or Quince Therapeutics?
Quince Therapeutics (QNCX) is larger, with a market capitalization of $29.86M compared with $28.30M for Immutep (IMMP).
Which stock has performed better over the past year, IMMP or QNCX?
IMMP returned +90.10% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are Immutep and Quince Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.